Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial
Aurinia Pharmaceuticals Inc. announced promising results from the AURORA Renal Biopsy Sub-Study.
Uncategorized
Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
Avacta Group plc, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the first patient has been dosed in the fifth cohort of the first-in-human phase I trial of AVA6000.
Addex Completes $5.0 Million Equity Financing
Addex Therapeutics Ltd announced that it has completed the equity financing transaction entered into on April 3, 2023 with a leading institutional healthcare investor, pursuant to which the Company sold 7,999,998 shares in the form of 1,333,333 American Depositary Shares at a gross purchase price of $0.95 per ADS.
TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock
TransCode Therapeutics, Inc. announced that its previously announced sale of Series A Convertible Preferred Stock for an aggregate purchase price of $500,000 will not be consummated after the proposed purchaser advised the Company that it was not prepared to complete the transaction on the terms set forth in the Stock Purchase Agreement signed by the
Relief Therapeutics Announces Executive Leadership Team Change
RELIEF THERAPEUTICS Holding SA announced that Nermeen Varawalla, M.D., Ph.D., chief medical officer, will depart the Company in the second quarter of 2023 to pursue other opportunities.
Relief Therapeutics Announces Executive Leadership Team Change Read More »
Perfuse Therapeutics Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma
Perfuse Therapeutics announced that the US Food and Drug Administration has cleared the Investigational New Drug application for a Phase 1/2a clinical study of PER-001 Intravitreal Implant in patients with glaucoma.
Occlutech Receives Subscription Commitment of Bonds Amounting to EUR 40 million in Nominal Value Under a Total Frame of EUR 75 million to Finance US Expansion and Growth
Occlutech Holding AG, one of the world’s leading providers of minimally invasive structural heart disease devices, receives subscription commitment subject to certain conditions, of bonds to an aggregated amount of EUR 40 million.
AlzeCure Pharma publishes its Annual Report for 2022
AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that its Annual Report for 2022 has been published.
AlzeCure Pharma publishes its Annual Report for 2022 Read More »
Dr. Hamid Abbasi Performs First Advanced Inspired Spine Trans-Kambin OLLIF with Arrow Cage in South America with Dr. Hazem Nicola
Dr. Hamid Abbasi, a renowned spine surgeon and innovator, has successfully performed the first Inspired Spine Trans-Kambin Oblique Lateral Lumbar Interbody Fusion with Arrow Cage in South America.
Philips Trilogy Evo ventilators face another Class I recall
More trouble for Philips’ Respironics business as the company flags a problem with ventilators that could lead to under-delivery of oxygen due to inaccurate readings.
Philips Trilogy Evo ventilators face another Class I recall Read More »